Tailored-pharmacophore model to enhance virtual screening and drug discovery: a case study on the identification of potential inhibitors against drug-resistant Mycobacterium tuberculosis (3R)-hydroxyacyl-ACP dehydratases

Future Med Chem. 2017 Jun;9(10):1055-1071. doi: 10.4155/fmc-2017-0020. Epub 2017 Jun 20.

Abstract

Aim: Virtual screening (VS) is powerful tool in discovering molecular inhibitors that are most likely to bind to drug targets of interest. Herein, we introduce a novel VS approach, so-called 'tailored-pharmacophore', in order to explore inhibitors that overcome drug resistance. Methodology & results: The emergence and spread of drug resistance strains of tuberculosis is one of the most critical issues in healthcare. A tailored-pharmacophore approach was found promising to identify in silico predicted hit with better binding affinities in case of the resistance mutations in MtbHadAB as compared with thiacetazone, a prodrug used in the clinical treatment of tuberculosis.

Conclusion: This approach can potentially be enforced for the discovery and design of drugs against a wide range of resistance targets.

Keywords: MtbHadAB; molecular dynamic simulation; post-MD analysis; tailored pharmacophore; thiacetazone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Discovery*
  • Drug Evaluation, Preclinical
  • Enoyl-CoA Hydratase / antagonists & inhibitors*
  • Enoyl-CoA Hydratase / metabolism
  • Enzyme Inhibitors / chemical synthesis
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology*
  • Models, Molecular
  • Molecular Structure
  • Structure-Activity Relationship
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Tuberculosis, Multidrug-Resistant / enzymology

Substances

  • Enzyme Inhibitors
  • Enoyl-CoA Hydratase